Neumora Therapeutics (NMRA) Return on Capital Employed (2023 - 2026)

Neumora Therapeutics' Return on Capital Employed history runs 4 years deep, the most recent figure standing at 156.72% for Q1 2026.

• In Q1 2026, Return on Capital Employed fell 5059.0% year-over-year to 156.72%; the TTM figure through Mar 2026 stood at 156.72% (down 5059.0% YoY), while the FY2025 annual figure was 108.85%, down 3890.0% from the prior year.
• Return on Capital Employed was 156.72% for Q1 2026 at Neumora Therapeutics, up from 158.67% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 50.89% in Q4 2023 to a low of 158.67% in Q4 2025.
• Historically, Return on Capital Employed has averaged 104.44% across 4 years, with a median of 98.42% in 2024.
• The sharpest annual moves came in 2024 and 2025: Return on Capital Employed sank 3553 bps in 2024, then sank 7225 bps in 2025.
• A 4-year view of Return on Capital Employed shows it stood at 50.89% in 2023, then slumped by 70 bps to 86.42% in 2024, then slumped by 84 bps to 158.67% in 2025, then rose by 1 bps to 156.72% in 2026.
• The last three Return on Capital Employed figures came in at 156.72% (Q1 2026), 158.67% (Q4 2025), and 140.35% (Q3 2025), per Business Quant data.